# Aksense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aksense

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.aksense.com
- Latest round: Seed (May 9, 2022)
- Investors on record: 1

## About

Founded in 2017 and headquartered in London, UK, Aksense develops innovative portable diagnostic biosensors aimed at quickly identifying healthcare-associated infections, enhancing response times in medical settings.Aksense specializes in portable diagnostics that swiftly detect healthcare-associated infections. The company was founded in 2017 in London, UK, by Asiye Karakullukçu and Mürsel Baydemir. Aksense has completed 2 deals with the most recent one occurring on May 9, 2022, during which they raised an undisclosed amount of SEED funding from returning investor SOSV.Aksense specializes in the development of innovative portable diagnostics biosensors designed to quickly identify healthcare-associated infections. Their core product, which has been released recently, allows for diagnosis within minutes, drastically reducing the time compared to traditional diagnostic methods that typically require 24 to 48 hours. This rapid diagnostic capability is critical in enabling healthcare providers to initiate timely treatment, thereby saving time, reducing costs, and ultimately preserving lives. The end users of Aksense's products primarily include hospitals and long-term care facilities within the European healthcare market, addressing the significant challenge posed by the estimated 8.9 million healthcare-associated infections occurring annually in these settings. Aksense's technology aims to support medical professionals in making informed treatment decisions while also promoting better hand hygiene practices among healthcare workers.Aksense operates on a transaction model that involves direct sales to healthcare institutions and possibly partnerships for broader distribution within the medical market. The company’s flagship biosensor is expected to be sold directly to hospitals and long-term care facilities. Given the urgency and necessity of rapid diagnostics in managing healthcare-associated infections, clients are positioned to rely on Aksense's technology to enhance patient care, potentially leading to recurring revenue through ongoing contracts or service agreements for maintenance and support.Following their latest funding round in May 2022, Aksense is focused on developing new products aimed at enhancing their diagnostic capabilities. Plans include expanding their presence in the European healthcare market and potentially exploring opportunities in other regions. The recent SEED funding will be utilized to accelerate the launch of these new diagnostics and support R&D efforts.

## Funding rounds

- Seed, May 9, 2022 — SOSV
- Seed, Oct 3, 2019 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed